Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Common Equity (2016 - 2025)

Historic Common Equity for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to $1.1 million.

  • NovaBay Pharmaceuticals' Common Equity rose 345.15% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 345.15%. This contributed to the annual value of -$129000.0 for FY2024, which is 10389.26% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Common Equity of $1.1 million as of Q3 2025, which was up 345.15% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Common Equity registered a high of $17.7 million during Q1 2022, and its lowest value of -$617000.0 during Q2 2024.
  • Its 5-year average for Common Equity is $7.3 million, with a median of $8.6 million in 2023.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Common Equity plummeted by 10720.54% in 2024, and later skyrocketed by 375437.5% in 2025.
  • NovaBay Pharmaceuticals' Common Equity (Quarter) stood at $10.2 million in 2021, then grew by 3.77% to $10.6 million in 2022, then plummeted by 68.6% to $3.3 million in 2023, then tumbled by 103.89% to -$129000.0 in 2024, then soared by 959.69% to $1.1 million in 2025.
  • Its Common Equity was $1.1 million in Q3 2025, compared to $4.2 million in Q2 2025 and $6.2 million in Q1 2025.